XML 68 R55.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative and Licensing Agreements - Revenue Recognition (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2017
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue recognized   $ 11,564,000 $ 29,039,000 $ 30,150,000 $ 12,500,000 $ 3,500,000 $ 40,603,000 $ 46,150,000 $ 109,020,000
Research collaboration                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue recognized             20,100,000 20,100,000 34,200,000
Milestone                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue recognized             20,500,000 26,000,000 5,000,000
Licensing                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue recognized               100,000 69,800,000
United States                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue earned             40,600,000 30,200,000 106,300,000
Non - United States                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue earned               16,000,000 2,700,000
Alexion Pharmaceuticals, Inc.                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue earned             20,000,000   5,000,000
Amgen, Inc.                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue earned             600,000 10,000,000 31,200,000
CSL Limited                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue earned               3,500,000  
MorphoSys                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue earned               12,500,000  
Novo Nordisk A/S                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue earned                 2,700,000
Novartis                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue earned             20,000,000 20,100,000 69,900,000
Other                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue earned               100,000 $ 200,000
2009 Research License and Commercialization Agreement | CSL Limited                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Deferred revenue   0         0    
Collaboration And License Agreement | MorphoSys                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestone payment $ 12,500,000                
Deferred revenue   0         0    
Collaboration And License Agreement | Novo Nordisk A/S                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Deferred revenue   0         0    
Collaboration And License Agreement | Novartis                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Deferred revenue   $ 40,100,000   $ 60,100,000     $ 40,100,000 $ 60,100,000